Pharmacy Times: What key sessions were highlighted at this year’s International Myeloma Society (IMS) Annual Meeting? And certainly here at IMS we're seeing a lot of data around that, so I think that's probably the most promising. So, lots of new things, lots of new ideas that also arose from those presentations that we see here at the IMS 2025 [Annual Meeting]. Paula Rodriguez-Otero, MD, PhD: I have the impression...the evolution in myeloma has been extraordinary. Xavier Leleu, MD, PhD: I think where we are now is extremely exciting.